Drug Profile
Ensituximab - Precision Biologics
Alternative Names: NEO-101; NEO-102; NPC-1CLatest Information Update: 26 Dec 2019
Price :
$50
*
At a glance
- Originator Neogenix Oncology
- Developer Duke University Medical Center; H. Lee Moffitt Cancer Center and Research Institute; Johns Hopkins Medical Institutions; Montefiore Medical Center; National Cancer Institute (USA); Precision Biologics; University of North Carolina; University of Texas Southwestern Medical Center; Yale University School of Medicine
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer; Pancreatic cancer
Most Recent Events
- 19 Dec 2019 Precision Biologics terminates a phase I/II trial in Pancreatic Cancer in USA due to trial futility as per DSMB recommendation (NCT01834235)
- 02 Aug 2019 Phase II development is ongoing in the US
- 26 Feb 2018 Ligand Pharmaceuticals, prior to February 2018, acquires the economic rights to certain programmes based on Selexis owned SUREtechnology platform, including the ensituximab programme